RT Journal Article
SR Electronic
T1 Continuous positive airway pressure face-mask ventilation to manage massive influx of patients requiring respiratory support during the SARS-CoV-2 outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.01.20118018
DO 10.1101/2020.06.01.20118018
A1 S. Alviset
A1 Q. Riller
A1 J. Aboab
A1 K. Dilworth
A1 PA. Billy
A1 Y. Lombardi
A1 M. Azzi
A1 L. Ferreira Vargas
A1 L. Laine
A1 M. Lermuzeaux
A1 N. Memain
A1 D. Silva
A1 T. Tchoubou
A1 D. Ushmorova
A1 H. Dabbagh
A1 S. Escoda
A1 R. Lefrançois
A1 A. Nardi
A1 A. Ngima
A1 V. Ioos
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.01.20118018.abstract
AB Background Since December 2019, a global outbreak of coronavirus disease (COVID-19) is responsible for massive influx of patients with acute respiratory failure in hospitals. We describe the characteristics, clinical course, and outcomes of COVID-19 patients treated with continuous positive airway pressure (CPAP) in a large public hospital in France.Method It is a single centre retrospective observational cohort. From 27th March to 23rd April, consecutive patients who had signs of respiratory failure or were unable to maintain an SpO2 > 90%, despite receiving 10 to 15 l/min of oxygen with a non-rebreather mask, were treated by CPAP with a face-mask unless the ICU physician judged that immediate intubation was indicated. The main outcomes under study were reasons for CPAP discontinuation and mortality.Results A total of 585 patients were admitted in Delafontaine hospital for severe COVID-19. ICU was quickly overwhelmed. Fifty-nine out of 159 (37%) patients requiring ICU care had to be referred to other hospitals. CPAP therapy was initiated in 49 patients and performed out of ICU in 41 (84%). SARS-CoV2 pneumonia was confirmed by PCR from respiratory tract in 39 (79%) patients and by thoracic CT scan in the remaining patients. CPAP was performed out of ICU in 41 (84%) cases. Median age was 65 years (IQR=54-71). Median duration of CPAP treatment was 3 days (IQR=1-5). Reasons for discontinuation of CPAP were intubation for invasive ventilation in 25 (51%) patients, improvement in 16 (33%), poor tolerance in 6 (12%) and death in 2 (4%). A decision not to intubate had been taken for the 2 patients who died while on CPAP.Conclusions Treatment with CPAP is feasible and safe in a non-ICU environment in the context of a massive influx of patients. One third of these patients with high oxygen requirements did not eventually need invasive ventilation.What is the key question?What is the best respiratory support strategy to manage a massive influx of patients with hypoxemic respiratory failure despite high-flow oxygen delivered with a non-rebreather mask?What is the bottom line?Continuous positive airway pressure face mask ventilation delivered in non-ICU wards to patients who do not require immediate intubation is feasible and safe.Why read on?Face mask ventilation with CPAP should be considered as an option of respiratory support in the context of the on-going COVID-19 pandemic and limited availability of ICU beds.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding required.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the national ethics review board (CNRIPH - Commission Nationale des Recherches Impliquant la Personne Humaine) under the number 2020-A01396-33. The patients or their next-of-kin were informed by mail about the data collection process and their right to oppose. The database was declared to the Commission Nationale Informatique et Libertes (CNIL) under the number 2217928.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, VI. The data are not publicly available due to their containing information that could compromise the privacy of research participants.